ALK has obtained European approval for its HDM-SLIT (house dust mite sublingual allergy immunotherapy tablet) against allergic rhinitis and allergic...
Merck announced that the FDA has accepted for review the Biologics License Application (BLA) for MK-8237, Merck’s house dust mite...
ALK has presented trial results on Mitizax (sublingual allergy immunotherapy tablet or SLIT-tablet) for House Dust Mite (HDM) respiratory Allergic...
ALK has announced that The Journal of the American Medical Association (JAMA) has published results from a Phase III clinical...
ALK has announced that its house dust mite sublingual allergy immunotherapy (SLIT) tablet Acarizax has had its approval in 12...
Merck has submitted a Biologics License Application (BLA) to the FDA for its house dust mite (HDM) sublingual allergy immunotherapy...